| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/00008571-200203000-00006 |
| P698 | PubMed publication ID | 11875366 |
| P50 | author | Stephen C Strom | Q40919746 |
| Ann K Daly | Q42383270 | ||
| P2093 | author name string | Erin G Schuetz | |
| Jiong Zhang | |||
| Jatinder K Lamba | |||
| Yvonne S Lin | |||
| Paul B Watkins | |||
| Kenneth Thummel | |||
| P2860 | cites work | Pharmacokinetics of nifedipine slow release tablet in Mexican subjects: further evidence for an oxidation polymorphism | Q41330176 |
| P433 | issue | 2 | |
| P304 | page(s) | 121-132 | |
| P577 | publication date | 2002-03-01 | |
| P1433 | published in | Pharmacogenetics and Genomics | Q10534561 |
| P1476 | title | Common allelic variants of cytochrome P4503A4 and their prevalence in different populations | |
| P478 | volume | 12 |
| Q45057856 | A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin |
| Q35842159 | Assessing the function of genetic variants in candidate gene association studies |
| Q89228158 | Association of CYP2C19*2 and ALDH1A1*1/*2 variants with disease outcome in breast cancer patients: results of a global screening array |
| Q33937239 | Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors |
| Q44613016 | CYP2C19‐ and CYP3A4‐Dependent Omeprazole Metabolism in West Mexicans |
| Q28244721 | CYP3A phenotypes and genotypes in North Indians |
| Q33910537 | CYP3A variation and the evolution of salt-sensitivity variants |
| Q35825323 | CYP3A5 phenotype-genotype correlations in a British population |
| Q36305439 | Cancer treatment and pharmacogenetics of cytochrome P450 enzymes |
| Q37406300 | Carbonated soft drinks alter hepatic cytochrome P450 isoform expression in Wistar rats |
| Q30939373 | Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population |
| Q44502093 | Characterization of CYP1A2, CYP2C19, CYP3A4 and CYP3A5 polymorphisms in South Brazilians |
| Q28741680 | Comparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variants |
| Q27331784 | Cytochrome P450 2B diversity and dietary novelty in the herbivorous, desert woodrat (Neotoma lepida) |
| Q35564329 | Cytochrome P450 3A and their regulation |
| Q35992745 | Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters |
| Q33646358 | Drug focus: Pharmacogenetic studies related to cyclophosphamide-based therapy |
| Q34099716 | Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. |
| Q90433604 | Effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its active metabolites |
| Q64933146 | Enzymatic Activities of CYP3A4 Allelic Variants on Quinine 3-Hydroxylation In Vitro. |
| Q39844481 | Evaluation of the Effects of Cytochrome P450 Nonsynonymous Single-Nucleotide Polymorphisms on Tanshinol Borneol Ester Metabolism and Inhibition Potential |
| Q34500741 | Fatal methadone toxicity: potential role of CYP3A4 genetic polymorphism |
| Q36474869 | Functional constraints on the constitutive androstane receptor inferred from human sequence variation and cross-species comparisons |
| Q38220008 | Functional gene variants of CYP3A4. |
| Q57093701 | Genetic analysis of drug metabolizing phase-I enzymes CYP3A4 in Tibetan populations |
| Q28212042 | Genetic contribution to variable human CYP3A-mediated metabolism |
| Q26823434 | Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review |
| Q36802054 | Genetic markers in CYP2C19 and CYP2B6 for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus |
| Q55281929 | Genetic polymorphisms in very important pharmacogenomic variants in the Zhuang ethnic group of Southwestern China: A cohort study in the Zhuang population. |
| Q28543477 | Genome-wide discovery of drug-dependent human liver regulatory elements |
| Q45224264 | Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients |
| Q52565287 | Impact of the CYP3A5*1 Allele on the Pharmacokinetics of Tacrolimus in Japanese Heart Transplant Patients. |
| Q35918055 | Importance of patient selection when determining the significance of the CYP3A5 polymorphism in clinical trials |
| Q40607751 | Increased transcriptional activity of the CYP3A4*1B promoter variant |
| Q80981339 | Interethnic variability of ERCC2 polymorphisms |
| Q37142009 | Interindividual variability of methadone response: impact of genetic polymorphism |
| Q35642257 | Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs |
| Q89017975 | Nutritional Status Differentially Alters Cytochrome P450 3A4 (CYP3A4) and Uridine 5'-Diphospho-Glucuronosyltransferase (UGT) Mediated Drug Metabolism: Effect of Short-Term Fasting and High Fat Diet on Midazolam Metabolism |
| Q37619585 | Patients with CYP3A4*1G genetic polymorphism consumed significantly lower amount of sufentanil in general anesthesia during lung resection |
| Q37376199 | Perioperative genomic profiles using structure-specific oligonucleotide probes |
| Q36424755 | Pharmacogene regulatory elements: from discovery to applications |
| Q37439873 | Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients |
| Q35772582 | Pharmacogenetic determinants of outcome in acute lymphoblastic leukaemia |
| Q35172002 | Pharmacogenetics in Ghana: reviewing the evidence |
| Q28252209 | Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response |
| Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
| Q46118142 | Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals |
| Q46726161 | Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity |
| Q28287172 | Pharmacogenomic assessment of carboxylesterases 1 and 2 |
| Q36727952 | Pharmacogenomics in pediatric leukemia |
| Q27692687 | Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine |
| Q64075058 | Polymorphism in Cytochrome P450 3A4 Is Ethnicity Related |
| Q46608345 | Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals |
| Q36989348 | Population pharmacokinetics of unbound and total drug concentrations following intravenously administered carbamazepine in elderly and younger adult patients with epilepsy |
| Q37369341 | Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans |
| Q34278794 | Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition |
| Q33829773 | Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA. |
| Q46511487 | Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients |
| Q33683890 | Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex |
| Q46237120 | The CYP3A4*18 genotype in the cytochrome P450 3A4 gene, a rapid metabolizer of sex steroids, is associated with low bone mineral density |
| Q37513374 | The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy |
| Q33749037 | The PXR rs7643645 polymorphism is associated with the risk of higher prostate-specific antigen levels in prostate cancer patients |
| Q24564967 | Tricyclic antidepressant pharmacology and therapeutic drug interactions updated |
| Q35579020 | Urinary 6?-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals |
| Q57550164 | Use of High Doses of Quetiapine in Bipolar Disorder Episodes are not Linked to High Activity of Cytochrome P4503A4 and/or Cytochrome P4502D6 |
| Q36729620 | Various pharmacogenetic aspects of antiepileptic drug therapy: a review |
Search more.